Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


For Some VCs And Execs, Familiarity Breeds More Start-Ups

This article was originally published in Start Up

Executive Summary

As biotech funding dwindles, investors are looking for ways to repurpose the technology, platforms, and products – and to revisit lucrative relationships – from previous investments. Two recent company launches are perfect examples.

You may also be interested in...

Astellas Experiments With Partnering Models For a Phase IIa Ulcerative Colitis Compound

Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.

Biopharma Deal-Making In 2011: A Year Of Transition

Approvals jumped, venture retrenched and dealmakers expanded on 2010’s creativity. Pharma’s thirst for payer-friendly innovation and emerging markets infrastructure pushed M&A valuations skyward, and threw VCs and drugmakers closer together. The year 2011 was also when we said goodbye to Lipitor, hello to the euro crisis, and “see you soon” to biosimilars.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts